AP
ANIK icon

AHL Partners’s Anika Therapeutics ANIK Stock Holding History

AHL Partners’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-7,890
Closed -$458K – 1247
2017
Q3 		$458K Sell
7,890
-9,296
-54% -$486K 0.01% 1077
2017
Q2 		$848K Sell
17,186
-3,113
-15% -$143K 0.02% 829
2017
Q1 		$882K Buy
+20,299
New +$969K 0.02% 810
2016
Q4 		– Sell
-7,721
Closed -$369K – 1041
2016
Q3 		$369K Buy
7,721
+3,116
+68% +$154K 0.01% 918
2016
Q2 		$247K Buy
+4,605
New +$217K 0.01% 742

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

AHL Partners's ANIK Position: Q4 2017 in Review

AHL Partners sold out of Anika Therapeutics (ANIK) in Q4 2017, closing a stake of 7,890 shares — an estimated $458K sold.

AHL Partners first reported a position in ANIK in Q2 2016 and held it in 5 quarters. The position peaked at $882K in Q1 2017. 172 funds tracked by Wall St. Rank hold ANIK as of Q4 2017.

  • AHL Partners reported no remaining Anika Therapeutics position as of Q4 2017 after selling out during the quarter.
  • AHL Partners sold 7,890 Anika Therapeutics shares in Q4 2017, an estimated $458K.
  • AHL Partners first reported a position in Anika Therapeutics in Q2 2016 and held it in 5 quarters.
  • AHL Partners's Anika Therapeutics position peaked at $882K in Q1 2017.
  • 172 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.